Research of HCV variants resistant to direct-acting antiviral agents
CHEN Jian-hong
XU Xiao-yuan
Abstract：The development of direct-acting antiviral agents (DAAs) leads the antiviral therapy of chronic hepatitis C (CHC) into a new era, and all-oral DAA combination regimens have highly antiviral activity with improved drug safety and reduced side effects. The selection of resistance-associated variants attenuates the antiviral activity of DAAs and brings a great challenge to the clinical application of DAAs. This review provides a systematic elaboration of HCV variants resistant to DAAs observed in clinical trials andin-vitrostudies and their natural prevalence in CHC patients, in the hope of providing useful information for predicting therapeutic efficacy and selecting DAA combination regimens.
Keywords：hepatitis Cdirect-acting antiviralsresistance-associated variants
Publication Date：2016-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 116-120 )